Abbott India Limited
ABBOTINDIA · Pharma · NSE
₹26,280
Current Market Price
Fair Value (DCF)
₹21,897
Discount to FV
-16.7%
Updated just now
YieldIQ Score
58/100
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
84%
ROE
32.5%
Debt/Equity
0.04
WACC
9.5%
Market Cap
₹55,843 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
44.1%
Return on capital employed
EV / EBITDA
25.1×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
84.2×
EBIT covers interest
Current Ratio
2.55×
Short-term liquidity
Asset Turnover
1.07×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹26,280
Bear case
Margin of Safety —
Implied upside -122.9%
Base case
Margin of Safety -25.0%
Implied upside -20.0%
Bull case
Margin of Safety +0.1%
Implied upside +0.1%
Ratio Trends
ABBOTINDIA · last 5 annual periods
ROE
32.5%
ROCE
44.1%
Operating Margin
—
Debt / Equity
0.04×
PE
35.5×
EV / EBITDA
25.1×
Historical Financials
ABBOTINDIA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹4910 Cr | ₹5347 Cr | ₹5847 Cr | ₹6409 Cr | ₹6929 Cr | +9.0% |
| EBITDA | ₹1165 Cr | ₹1360 Cr | ₹1701 Cr | ₹1970 Cr | ₹2180 Cr | +17.0% |
| EBIT | ₹1099 Cr | ₹1290 Cr | ₹1630 Cr | ₹1898 Cr | — | +14.6% |
| PAT | ₹799 Cr | ₹949 Cr | ₹1201 Cr | ₹1414 Cr | ₹1552 Cr | +18.1% |
| EPS (diluted) | ₹375.86 | ₹446.78 | ₹565.28 | ₹665.62 | — | +15.4% |
| CFO | ₹948 Cr | ₹893 Cr | ₹1213 Cr | ₹1012 Cr | ₹1319 Cr | +8.6% |
| CapEx | ₹-44.1 Cr | ₹-34.1 Cr | ₹-48.3 Cr | ₹-52.6 Cr | ₹-40.9 Cr | — |
| FCF | ₹904 Cr | ₹859 Cr | ₹1164 Cr | ₹959 Cr | ₹1278 Cr | +9.1% |
| Total Assets | ₹4224 Cr | ₹4556 Cr | ₹5193 Cr | ₹5917 Cr | ₹6502 Cr | +11.4% |
| Total Debt | ₹152 Cr | ₹113 Cr | ₹83.2 Cr | ₹197 Cr | ₹172 Cr | +3.2% |
| Shareholders' Equity | ₹2820 Cr | ₹3189 Cr | ₹3699 Cr | ₹4233 Cr | ₹4774 Cr | +14.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ABBOTINDIA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 GLENMARK GLENMARK | — | — | Pending | 13.0% | 44.2× |
 ALKEM ALKEM | — | — | Pending | 16.7% | 27.5× |
 BIOCON BIOCON | — | — | Pending | 1.1% | 151.6× |
 LAURUSLABS LAURUSLABS | — | — | Pending | 8.0% | — |
 IPCALAB IPCA Laboratories Limited | -47.9%-32.4% upside | 50 | Above Fair Value | 14.2% | 35.6× |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹1,760.00/sh
Last payout
2025-07-25
₹475.00
Peak payout
₹475.00
Trailing yield
1.81%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Abbott India Limited (ABBOTINDIA.NS) trades at 26280.00 vs a model fair value of 21897.19, a gap of -16.7%. Piotroski F-score: 6/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ABBOTINDIA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ABBOTINDIA →
Compare
Head-to-head with peers
Compare ABBOTINDIA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ABBOTINDIANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.